Business

Novo Nordisk raises its 2026 outlook for the third time this year as Wegovy pill sales beat forecasts

Danish drugmaker Novo Nordisk raised its full-year 2026 outlook on Wednesday for the third time this year after third-quarter sales of its Wegovy weight-loss pill beat analyst forecasts. The pill, launched in the United States in January, brought in 5.39 billion Danish crowns ($810 million) in the quarter, up 53% from the second quarter and above the 4.62 billion consensus. Adjusted operating profit rose 27% at constant exchange rates to 31.72 billion crowns, also above expectations. The company also said it will cut US list prices for Wegovy and Ozempic from January and that its finance chief will leave at the end of December.